Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 35, Issue 3-4, 2011, Pages 109-113

  Hao, Miao ^a   Wang, Wei ^b   Zhao, Yuqing ^c   Zhang, Ruiwen ^b   Wang, Hui ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

25 hydroxyprotopanaxadiol; Panax ginseng; Pancreatic cancer; Pharmacokinetics; Tissue distribution

Indexed keywords

25 HYDROXYPROTOPANAXADIOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; FRUIT; GINSENG; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS TUMOR; PLASMA CONCENTRATION-TIME CURVE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; GINSENOSIDES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, NUDE; PANAX; PANCREATIC NEOPLASMS; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79953787011     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-010-0022-9     Document Type: Article

References (29)

1. Attele AS, Wu JA, Yuan CS (1999) Ginseng pharmacology: Multiple constituents and multiple actions. Biochem Pharmacol 58: 1685-1693 (Pubitemid 29505408)
2. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
3. Coon JT, Ernst E (2002) Panax ginseng: A systematic review of adverse effects and drug interactions. Drug Saf 25:323-344 (Pubitemid 34634271)
4. Fuzzati N (2004) Analysis methods of ginsenosides. J Chromatogr B Analyt Technol Biomed Life Sci 812:119-133 (Pubitemid 39535405)
5. Hasegawa H (2004) Proof of the mysterious efficacy of ginseng: Basic and clinical trials: metabolic activation of ginsenoside: Deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 95:153-157 (Pubitemid 38899683)
6. Helms S (2004) Cancer prevention and therapeutics: Panax ginseng. Altern Med Rev 9:259-274 (Pubitemid 39299200)
7. Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
8. Jia WW, Bu X, Philips D et al (2004) Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol 82:431-437 (Pubitemid 39388382)
9. Kim HS, Lee EH, Ko SR et al (2004) Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 27:429-435
10. Li L, Sheng Y, Zhang J et al (2004) HPLC determination of four active saponins from Panax notoginseng in rat serum and its application to pharmacokinetic studies. Biomed Chromatogr 18:849-856 (Pubitemid 40089858)
11. Li K, Chen X, Xu J et al (2005) Liquid chromatography/tandem mass spectrometry for pharmacokinetic studies of 20(R)-ginsenoside Rg3 in dog. Rapid Commun Mass Spectrom 19:813-817 (Pubitemid 40349422)
12. Li G, Wang Z, Sun Y et al (2006) Ginsenoside 20(S)-protopanaxadiol inhibits the proliferation and invasion of human fibrosarcoma HT1080 cells. Basic Clin Pharmacol Toxicol 98:588-592
13. Mochizuki M, Yoo YC, Matsuzawa K et al (1995) Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)-and 20(S)-ginsenoside- Rg3, of red ginseng. Biol Pharm Bull 18:1197-1202
14. Nakata H, Kikuchi Y, Tode T et al (1998) Inhibitory effects of ginsenoside Rh2 on tumor growth in nude mice bearing human ovarian cancer cells. Jpn J Cancer Res 89:733-740 (Pubitemid 28401159)
15. Pang H, Wang HL, Fu L et al (2001) Pharmacokinetic studies of 20(R)-ginsenoside RG3 in human volunteers. Yao Xue Xue Bao 36:170-173 (Pubitemid 33629758)
16. Qian T, Cai Z, Wong RN et al (2005a) In vivo rat metabolism and pharmacokinetic studies of ginsenoside Rg3. J Chromatogr B Analyt Technol Biomed Life Sci 816:223-232 (Pubitemid 40143510)
17. Qian T, Cai Z, Wong RN et al (2005b) Liquid chromatography/mass spectrometric analysis of rat samples for in vivo metabolism and pharmacokinetic studies of ginsenoside Rh2. Rapid Commun Mass Spectrom 19:3549-3554 (Pubitemid 41691930)
18. Qian T, Jiang ZH, Cai Z (2006) High-performance liquid chromatography coupled with tandem mass spectrometry applied for metabolic study of ginsenoside Rb1 on rat. Anal Biochem 352:87-96
19. Sun J, Wang G, Haitang X et al (2005) Simultaneous rapid quantification of ginsenoside Rg1 and its secondary glycoside Rh1 and aglycone protopanaxatriol in rat plasma by liquid chromatography-mass spectrometry after solid-phase extraction. J Pharm Biomed Anal 38:126-132 (Pubitemid 40725098)
20. Wang H, Cai Q, Zeng X et al (1999a) Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 96:13989-13994
21. Wang H, Zou H, Kong L et al (1999b) Determination of ginsenoside Rg3 in plasma by solid-phase extraction and high-performance liquid chromatography for pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 731:403-409 (Pubitemid 29397609)
22. Wang W, Wang GJ, Xie HT et al (2007a) Determination of ginsenoside Rd in dog plasma by liquid chromatography-mass spectrometry after solid-phase extraction and its application in dog pharmacokinetics studies. J Chromatogr B Analyt Technol Biomed Life Sci 852:8-14 (Pubitemid 46839207)
23. Wang W, Zhao Y, Rayburn ER et al (2007b) In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 59:589-601 (Pubitemid 46295123)
24. Wang W, Rayburn ER, Zhao Y et al (2009) Novel ginsenosides 25-OH-PPD and 25-OCH3-PPD as experimental therapy for pancreatic cancer: anticancer activity and mechanisms of action. Cancer Lett 278:241-248
25. Xie HT, Wang GJ, Lv H et al (2005a) Development of a HPLC-MS assay for ginsenoside Rh2, a new anti-tumor substance from natural product and its pharacokinetic study in dogs. Eur J Drug Metab Pharmacokinet 30:63-67 (Pubitemid 40910766)
26. Xie HT, Wang GJ, Sun JG et al (2005b) High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 818:167-173
27. Xu QF, Fang XL, Chen DF (2003) Pharmacokinetics and bioavailability of ginsenoside Rb1 and Rg1 from Panax notoginseng in rats. J Ethnopharmacol 84:187-192 (Pubitemid 36324258)
28. Xu TM, Xin Y, Cui MH et al (2007) Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl) 120:584-588 (Pubitemid 46629914)
29. Yun TK, Lee YS, Lee YH et al (2001) Anticarcinogenic effect of Panax ginseng C.A. Meyer and identification of active compounds. J Korean Med Sci 16(Suppl):S6-18